Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul;32(4):722-730.
doi: 10.3904/kjim.2016.256. Epub 2017 Jun 26.

Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications

Junghoon Shin  1 , Youngil Koh  1 , Jeonghwan Youk  1 , Miso Kim  1 , Byung Soo Kim  2 , Chul Won Choi  2 , Hwa Jung Sung  2 , Yong Park  2 , Sung-Soo Yoon  1 , Inho Kim  1
Affiliations

Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications

Junghoon Shin et al. Korean J Intern Med. 2017 Jul.

Abstract

Background/aims: Although multiple myeloma (MM) is typically a disease of the elderly, a certain subset of extremely young patients exists. It is necessary to establish clinicopathological characteristics for this population.

Methods: We reviewed the medical records of MM patients whose age was 40 years or younger at diagnosis.

Results: A total of 32 patients were analyzed (male to female ratio 19:13, median age 37 years). According to International Staging System, 29%, 48%, and 16% were in stage I, II, and III, respectively. Light chain myeloma accounted for 30%. Clinically significant anemia, hypercalcemia, azotemia, and hypoalbuminemia were present in 29%, 28%, 13%, and 28%, respectively. Three or more lytic bone lesions were detected in 45% of the patients, whereas 13% had no lytic bone lesions. Regarding treatment, 79% of patients received autologous hematopoietic stem cell transplantation. After a median follow-up duration of 64 months, the 1-, 3-, and 5-year overall survival (OS) rates were 84%, 62%, and 54%, respectively. The median OS was 61 months for the entire cohort.

Conclusions: In our study, MM patients aged 40 years or younger at diagnosis showed no superior survival compared to those of the moderately elderly patients based on historical data.

Keywords: Hematopoietic stem cell transplantation; Multiple myeloma; Treatment outcome; Young adult.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Figure 1.
Figure 1.
(A) Progression-free survival (PFS) after first-line treatment. (B) PFS after first-line treatment stratified by whether the patients received autologous hematopoietic stem cell transplantation (aHSCT) as part of the first-line treatment. (C) Overall survival (OS). (D) OS stratified by whether the patients received aHSCT as part of the first-line treatment.
Figure 2.
Figure 2.
(A) Overall survival (OS) of subgroups divided by International Staging System (ISS) stage. (B) OS of subgroups divided into whole immunoglobulin (Ig)-secreting myeloma or light chain myeloma. (C) OS of subgroups divided by light chain subtype. (D) OS of subgroups divided by the presence of biopsy-proven plasmacytoma at diagnosis.
See this image and copyright information in PMC

References

    1. Bergsagel D. The incidence and epidemiology of plasma cell neoplasms. Stem Cells. 1995;13 Suppl 2:1–9. - PubMed
    1. Corso A, Klersy C, Lazzarino M, Bernasconi C. Multiple myeloma in younger patients: the role of age as prognostic factor. Ann Hematol. 1998;76:67–72. - PubMed
    1. Blade J, Kyle RA. Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma. 1998;30:493–501. - PubMed
    1. Ludwig H, Durie BG, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10549 patients from the International Myeloma Working Group. Blood. 2008;111:4039–4047. - PMC - PubMed
    1. Dimopoulos MA, Pouli A, Anagnostopoulos A, et al. Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis. Leuk Lymphoma. 2006;47:1553–1556. - PubMed

Substances